SF3B1mutations disrupt normal pre-mRNA splicing to cause disease. Drugs inhibiting the interaction between the SF3b complex and RNA or agents degrading auxiliary splicing factors are being tested as new avenues for targeted therapy in myeloid neoplasia (MN) with SF3B1mutations. Here we describe the ability of small molecules to restore altered RNA processes in SF3B1MTMN.